Lessons learned from conducting a serological survey for Japanese encephalitis after detecting the first cases in New South Wales, Australia, 2022.

Problem: The first known locally acquired cases of Japanese encephalitis virus (JEV) infection in New South Wales (NSW), Australia, were identified in March 2022. NSW Health (the state entity for health care in NSW), with its partner agencies, conducted a serological survey to identify the prevalence of JEV antibody responses in high-risk communities in NSW.

Context: JEV infection is rare in Australia; therefore, vaccination is not recommended for the majority of Australians.

The seroprevalence of antibodies to Japanese encephalitis virus in five New South Wales towns at high risk of infection, 2022: a cross-sectional serosurvey.

Objectives: To determine the proportion of people in New South Wales towns at high risk of Japanese encephalitis virus (JEV) infections during the 2022 outbreak; to identify risk factors for JEV infection.

Study Design: Cross-sectional serosurvey study of the seroprevalence of JEV-specific antibodies in NSW.

Setting, Participants: Convenience sample of people (all ages) from five regional NSW towns deemed to be at high risk of JEV infections after first outbreak of Japanese encephalitis in southeastern Australia in early 2022 (Balranald, Corowa, Dubbo, Griffith, Temora), 21 June - 22 July 2022.

FluTracking: Weekly online community-based surveillance of influenza-like illness in Australia, 2019 Annual Report.

FluTracking provided evidence for an early, long, but moderate influenza season in the Australian community compared to prior years. Influenza-like illness (ILI) activity in 2019 peaked earlier (week ending 16 June) than any season on record in FluTracking data. ILI attack rates were above average early in the 2019 season (peak of 2.

Provision and delivery of survivorship care for adult patients with haematological malignancies: A scoping review protocol.

Introduction: Haematological malignancies are a heterogenous group of blood and lymphatic cancers. Survivorship care is a similarly diverse term concerning patients' health and wellbeing from diagnosis to end of life. Survivorship care for patients with haematological malignancies has traditionally been consultant-led and secondary care-based, although shifts away from this model have been occurring, largely via nurse-led clinics and interventions with some remote monitoring.